RPRD1A and cancer: To deeply understand the regulation of β-catenin for effective cancer therapies, many factors have been identified that interact with β-catenin, such as Maml1, which activates Wnt signaling pathway [46], whereas these factors, including p15RS and Sox9, bind to β-catenin and suppress the transcription activity of TCF/LEF reporter [47], [48].